Glucagon-like peptide-1 receptor agonists (GLP-1 RA) significantly reduce the risk for clinically meaningful chronic kidney disease (CKD) progression and major adverse cardiovascular events (MACE) in ...

In line with trial results, real-world data suggest GLP-1 receptor agonists have certain benefits in patients with moderate to severe chronic kidney disease (CKD).

Roche Holding AG delivered a strong set of 2024 earnings. Guidance for 2025 suggests this will be a transitional year ahead, ...

A/S, a global healthcare company specializing in diabetes care and other chronic conditions, has been at the forefront of the rapidly expanding GLP-1 market. With a market capitalization of $376.79 ...

Scouted selects products independently. If you purchase something from our posts, we may earn a small commission. Unless you ...

The study included nearly 2 million patients, making it the largest ever conducted on this group of glucagon-like peptide-1 receptor agonists ... a KFF analysis, the list price for GLP-1 drugs ...

Real-world data show that treatment with glucagon-like peptide-1 receptor agonists (GLP1-RA ... Please see the original reference for a full list of authors’ disclosures. References: Zhang ...

Yet the soaring enthusiasm for so-called glucagon-like peptide-1 receptor agonists ... For instance, at the start of 2024, the US list prices of Ozempic (Novo Nordisk) and Mounjaro (Eli Lilly ...

The medications are known as glucagon-like peptide-1 receptor agonists (GLP-1RA ... Add surgical tweaks to fix so-called "Ozempic face" to the list of top trending cosmetic procedures, as tallied ...